Regentis Biomaterials Ltd (RGNT) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access RGNT Annual Balance Sheets →
Balance sheet patterns shown here provide context for understanding Regentis Biomaterials Ltd's financial stability and long-term positioning.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Dec 31 2025) 0 0 0
Assets
Cash & cash equivalent8.95
Cash & Short-term Investments8.00
Derivatives, Collateral, Regulatory, Deferred0.00
Other Current Assets0.33
Prepaid Expense And Other Assets Current0.00
Total Current Assets9.29
Equipment/Property/Plant Net0.03
Long-term investments0.00
Tax Assets, Noncurrent0.00
Other Assets, Noncurrent0.03
Total Assets9.35
Liabilities
Accounts Payable1.45
Accrued Liabilities, Current0.00
Short-term Debt DE10.00
Other Liabilities, Current0.21
Total Current Liabilities1.65
Total Long-term Debt0.00
Other liabilities, Noncurrent0.02
Total Liabilities1.67
Stockholders' Equity
Additional Paid In Capital Common Stock66.08
Retained Earnings / Accumulated Deficit-58.39
Common Stockholder's Equity7.68
Total Stockholder's Equity7.68
Liabilities & Stockholder's Equity9.35
4 historic quarters locked

Sign in to unlock the full Regentis Biomaterials Ltd balance sheet history.

About Regentis Biomaterials Ltd Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 20-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001213900-26-019917

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API Connect Your AI